Clinical Trials Sponsored by HitGen Inc.

Total 36371 results

Biogen

Completed

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (FOCUS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
Biogen

Completed

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Biogen

Completed

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (StarTec)

Multiple Sclerosis, Relapsing-Remitting

Italy
Biogen

Completed

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (TOLERATE)

Relapsing-Remitting Multiple Sclerosis

Germany
Biogen

Completed

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Systemic Lupos Erythematosus, SLE

United States
Biogen

Completed

PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants

Healthy | Trigeminal Neuralgia

United Kingdom
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
Biogen

Completed

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Biogen

Completed

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Healthy

Netherlands, United States
Biogen

Completed

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Completed

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (ASSURE)

Relapsing-Remitting Multiple Sclerosis

United Kingdom, Ireland
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Relapsing-Remitting Multiple Sclerosis

Italy
Biogen

Completed

Absorption, Metabolism, and Excretion Study of BIIB074

Neuropathic Pain

United States
Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen

Terminated

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (RESPOND-EXT)

Rheumatoid Arthritis

Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russian Federation, United Kingdom
Biogen

Terminated

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Biogen

Withdrawn

Systemic Sclerosis Clinical and Biomarker Study

Healthy | Systemic Sclerosis
Biogen

Completed

Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study (AVAIL)

Multiple Sclerosis

Belgium
Biogen

Completed

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

Healthy

United States, Italy, France
Biogen

Terminated

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

France, United States, Belgium, Australia, Austria, Poland, Canada, United Kingdom
Biogen

Completed

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

GIST

United States
Biogen

Completed

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy (SPRINT)

Sciatica | Radiculopathy | Painful Lumbar Radiculopathy

United States
Biogen

Completed

Single-Dose Study of a New Formulation of BIIB061

Multiple Sclerosis

United States
Biogen

Completed

TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World (TYGRIS - ROW)

Multiple Sclerosis

Germany
Biogen

Completed

Canadian Avonex PEN Productivity Study (CAPPS)

Multiple Sclerosis

Canada
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Biogen

Completed

Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (PERSIST)

Multiple Sclerosis

Sweden, France, United Kingdom, Germany, Denmark, Netherlands, Slovakia, Switzerland, Norway, Portugal
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
Biogen

Terminated

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

Multiple Sclerosis

United States
Biogen

Completed

A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers

Healthy

United States
Biogen

Completed

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Singapore, Taiwan, United Kingdom
Biogen

Completed

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Czech Republic, Poland, Slovakia, India, Australia, Canada
Biogen

Completed

Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Biogen

Terminated

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance (CHAMPIONS CONT)

Multiple Sclerosis

United States
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
Biogen

Completed

A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

Healthy

China
Biogen

Completed

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

Healthy Volunteers

United States
Biogen

Completed

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Australia, Canada, United Kingdom
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Biogen

Completed

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Sweden, Czech Republic, France, Russian Federation, Turkey, United Kingdom, Germany, Lithuania, Romania, United States, Austria
Biogen

Completed

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Lymphoma | Tumors

United Kingdom, United States

3

Subscribe